Haiam Abdel Raouf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haiam Abdel Raouf has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Hala Tabie El-Bassyouni
Clinical Genetics Department, Human Genetics and Genome Research Institute, National Research Centre, Cairo, Egypt
4 shared publications Iman Helwa
4 shared publications- Shams Kholoussi
Immunogenetics Department, Human Genetics and Genome Research Division, National Research Centre, Giza, Egypt
3 shared publications - Alaaeldin Gamal Fayez
Molecular Genetics and Enzymology Department, Human Genetics and Genome Research Institute, National Research Centre, Giza, Egypt
2 shared publications - Hala G. Elnady
Professor of Pediatrics, Department of Pediatrics, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
2 shared publications Mohamed Shaker
2 shared publications
Latest Publications
- Open Access
- 4 May 2023
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 18 (6) , 1244-1253
New drug-like small molecule antagonizes phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in patients with conotruncal heart defects
- 4 May 2023
- Published by Elsevier in Journal of Taibah University Medical Sciences
- Vol. 18 (6) , 1244-1253
Open AccessNew drug-like small molecule antagonizes phosphatidylinositol (3,4,5)-trisphosphate (PIP3) in patients with conotruncal heart defects
- Open Access
- 30 September 2021
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 14 (3) , 1351-1358
Differential Expression of micro RNAs and their Association with the Inflammatory Markers in Familial Mediterranean Fever Patients
Background: Familial Mediterranean fever (FMF) is an auto inflammatory genetic disease resulted from the mutation of pyrin, which contributes to the formation of inflamma some complex. Therefore, activation of cytokines is one of the hallmarks of FMF pathogenesis. This study aimed to investigate the role of miRNAs as regulatory biomarkers for inflammation in patients with FMF. Methods: 50 FMF patients and 25 healthy subjects were included in this study. Q RT-PCR was used to determine plasma expressions of miR-181a and miR-125a, while IFN-γ and IL-17 were estimated using ELISA technique. Results: Our results indicated that, the expression of miR-181a was significantly decreased (p = 0.006) while miR-125a expression was insignificantly reduced (p = 0.101) also IL-17 levels were significantly higher(p = 0.003) and plasma IFN-γ levels were insignificantly increased (p = 0.322) in FMF patients than control group. Correlation analysis revealed a positive correlation between miR-181a expression and lymphocyte percentages (p = 0.048),while a significant negative association was observed between miR-125a and C-reactive protein (CRP) (p = 0.005) in FMF patients. However, there were no associations between miR-125a and miR-181a with IFN-γ and IL-17 in FMF patients. Conclusion: miR-181a and miR-125a could be used as regulatory biomarkers for inflammation in FMF patients.
- 30 September 2021
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 14 (3) , 1351-1358
Open AccessDifferential Expression of micro RNAs and their Association with the Inflammatory Markers in Familial Mediterranean Fever Patients
Background: Familial Mediterranean fever (FMF) is an auto inflammatory genetic disease resulted from the mutation of pyrin, which contributes to the formation of inflamma some complex. Therefore, activation of cytokines is one of the hallmarks of FMF pathogenesis. This study aimed to investigate the role of miRNAs as regulatory biomarkers for inflammation in patients with FMF. Methods: 50 FMF patients and 25 healthy subjects were included in this study. Q RT-PCR was used to determine plasma expressions of miR-181a and miR-125a, while IFN-γ and IL-17 were estimated using ELISA technique. Results: Our results indicated that, the expression of miR-181a was significantly decreased (p = 0.006) while miR-125a expression was insignificantly reduced (p = 0.101) also IL-17 levels were significantly higher(p = 0.003) and plasma IFN-γ levels were insignificantly increased (p = 0.322) in FMF patients than control group. Correlation analysis revealed a positive correlation between miR-181a expression and lymphocyte percentages (p = 0.048),while a significant negative association was observed between miR-125a and C-reactive protein (CRP) (p = 0.005) in FMF patients. However, there were no associations between miR-125a and miR-181a with IFN-γ and IL-17 in FMF patients. Conclusion: miR-181a and miR-125a could be used as regulatory biomarkers for inflammation in FMF patients.
- 1 March 2019
- Published by Elsevier in Gene Reports
- Vol. 14, 118-123
The association of +1150A polymorphism with low GH level in isolated growth hormone deficiency (IGHD) patients
- 1 March 2019
- Published by Elsevier in Gene Reports
- Vol. 14, 118-123
The association of +1150A polymorphism with low GH level in isolated growth hormone deficiency (IGHD) patients
- 1 July 2016
- Published by Elsevier in Archives of Medical Research
- Vol. 47 (5) , 349-355
Relationship Between Serum microRNA155 and Telomerase Expression in Hepatocellular Carcinoma
- 1 July 2016
- Published by Elsevier in Archives of Medical Research
- Vol. 47 (5) , 349-355
Relationship Between Serum microRNA155 and Telomerase Expression in Hepatocellular Carcinoma
- 1 July 2016
- Published by Egyptian Knowledge Bank in Middle East Journal of Medical Genetics
- Vol. 5 (2) , 60-64
Evaluation of telomerase activity in lymphoproliferative disorders
- 1 July 2016
- Published by Egyptian Knowledge Bank in Middle East Journal of Medical Genetics
- Vol. 5 (2) , 60-64
Evaluation of telomerase activity in lymphoproliferative disorders
- 28 March 2016
- Published by Modern Science Publishers in Journal of Experimental and Applied Animal Sciences
- Vol. 2 (1) , 10-22
Nigella sativa and Aloe vera protection against doxorubicin hepatotoxicity
Nigella sativa and Aloe vera protection against doxorubicin hepatotoxicity
- 28 March 2016
- Published by Modern Science Publishers in Journal of Experimental and Applied Animal Sciences
- Vol. 2 (1) , 10-22
Nigella sativa and Aloe vera protection against doxorubicin hepatotoxicity
Nigella sativa and Aloe vera protection against doxorubicin hepatotoxicity
- Open Access
- 1 October 2015
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 16 (4) , 367-374
Metabolic abnormalities in young Egyptian women with polycystic ovary syndrome and their relation to ADIPOQ gene variants and body fat phenotype
- 1 October 2015
- Published by Springer Nature in Egyptian Journal of Medical Human Genetics
- Vol. 16 (4) , 367-374
Open AccessMetabolic abnormalities in young Egyptian women with polycystic ovary syndrome and their relation to ADIPOQ gene variants and body fat phenotype
- Open Access
- 5 March 2015
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 3 (1) , 37-45
Prediction of Gut Wall Integrity Loss in Viral Gastroenteritis by Non-Invasive Marker
BACKGROUND: Intestinal fatty acid binding proteins (I-FABPs) are mainly expressed in the intestinal villi, which are the initial site of destruction in viral gastroenteritis.AIM: This study was designed to assess serum I-FABPs as a predictor of gut wall integrity loss in viral gastroenteritis.PATIENTS AND METHODS: This case-control cross-sectional study was conducted on 93 cases of acute viral gastroenteritis. Twenty-eight healthy children matching in age were recruited as control group. Serum I-FABPs were measured using ELISA technique. Viral detection and typing were done by PCR for adenovirus, and by Reverse transcriptase PCR for rotavirus, astrovirus and norovirus.RESULTS: Serum I-FABPs level was significantly higher in the cases compared to the controls and was also higher in the 46 rotavirus gastroenteritis cases compared to other viral gastroenteritis cases. Serum I- FABPs level was significantly higher in severely dehydrated cases as compared to mildly dehydrated ones (P=0.037).CONCLUSION: Serum I-FABPs could be used as an early and sensitive predictor marker of gut wall integrity loss in children with viral gastroenteritis and its level can indicate case severity.
- 5 March 2015
- Published by Scientific Foundation Spiroski (publications) in Open Access Macedonian Journal of Medical Sciences
- Vol. 3 (1) , 37-45
Open AccessPrediction of Gut Wall Integrity Loss in Viral Gastroenteritis by Non-Invasive Marker
BACKGROUND: Intestinal fatty acid binding proteins (I-FABPs) are mainly expressed in the intestinal villi, which are the initial site of destruction in viral gastroenteritis.AIM: This study was designed to assess serum I-FABPs as a predictor of gut wall integrity loss in viral gastroenteritis.PATIENTS AND METHODS: This case-control cross-sectional study was conducted on 93 cases of acute viral gastroenteritis. Twenty-eight healthy children matching in age were recruited as control group. Serum I-FABPs were measured using ELISA technique. Viral detection and typing were done by PCR for adenovirus, and by Reverse transcriptase PCR for rotavirus, astrovirus and norovirus.RESULTS: Serum I-FABPs level was significantly higher in the cases compared to the controls and was also higher in the 46 rotavirus gastroenteritis cases compared to other viral gastroenteritis cases. Serum I- FABPs level was significantly higher in severely dehydrated cases as compared to mildly dehydrated ones (P=0.037).CONCLUSION: Serum I-FABPs could be used as an early and sensitive predictor marker of gut wall integrity loss in children with viral gastroenteritis and its level can indicate case severity.
- 1 June 2014
- Published by Wolters Kluwer Health in Medical Research Journal
- Vol. 13 (1) , 21-26
Urinary liver-type fatty acid-binding protein for early detection of acute kidney injury in neonatal sepsis
Objective The aim of the study was to determine the prognostic ability of urinary liver-type fatty acid-binding protein (L-FABP) and to further characterize its sensitivity and specificity as a biomarker of acute kidney injury (AKI). Patients and methods This case–control study was carried out on 42 septic neonates who developed AKI of the 60 critically ill neonates admitted to Neonatal Intensive Care Unit of Al-Zahraa Hospital. Urine L-FABP at the time of ICU admission was quantitated to be compared with serum creatinine at admission and after 48 h. Results AKI patients showed significantly higher level of urinary L-FABP than non-AKI patients. The diagnostic performance, assessed by the area under the receiver operating characteristic curve, was 0.743 for L-FABP, demonstrating its usefulness in diagnosing AKI. Conclusion Urinary L-FABP seems to be promising both for the diagnosis of AKI and for the prediction of prognosis in heterogeneous ICU patients. It needs to be further validated for clinical utility.
- 1 June 2014
- Published by Wolters Kluwer Health in Medical Research Journal
- Vol. 13 (1) , 21-26
Urinary liver-type fatty acid-binding protein for early detection of acute kidney injury in neonatal sepsis
Objective The aim of the study was to determine the prognostic ability of urinary liver-type fatty acid-binding protein (L-FABP) and to further characterize its sensitivity and specificity as a biomarker of acute kidney injury (AKI). Patients and methods This case–control study was carried out on 42 septic neonates who developed AKI of the 60 critically ill neonates admitted to Neonatal Intensive Care Unit of Al-Zahraa Hospital. Urine L-FABP at the time of ICU admission was quantitated to be compared with serum creatinine at admission and after 48 h. Results AKI patients showed significantly higher level of urinary L-FABP than non-AKI patients. The diagnostic performance, assessed by the area under the receiver operating characteristic curve, was 0.743 for L-FABP, demonstrating its usefulness in diagnosing AKI. Conclusion Urinary L-FABP seems to be promising both for the diagnosis of AKI and for the prediction of prognosis in heterogeneous ICU patients. It needs to be further validated for clinical utility.